Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study
Both THP and THPy are effective first-line options for HER2-positive MBC. While THPy demonstrates a higher ORR and a trend toward longer PFS, it also carries a higher incidence of adverse events, particularly diarrhea. These findings offer preliminary insights that may help inform treatment decisions, pending further validation in prospective studies.
Authors
- Zongbi Yi (ORCID: https://orcid.org/0000-0002-7858-6633)
- Zhe-Yu Hu (ORCID: https://orcid.org/0000-0003-0932-9745)
- Binliang Liu (ORCID: https://orcid.org/0000-0002-3692-2272)
- Jian Deng (ORCID: https://orcid.org/0009-0005-6120-3084)
- Jiuda Zhao
- Yongxin Li (ORCID: https://orcid.org/0000-0001-5339-5411)
- Ronghua Feng
- Ning Xie (ORCID: https://orcid.org/0000-0002-4628-2299)
- Tao Wu (ORCID: https://orcid.org/0000-0003-2725-8442)
- Can Tian (ORCID: https://orcid.org/0000-0002-3675-4627)
- Quchang Ouyang
Institutions
- Hunan Institute of Science and Technology (CN)
- Qinghai University (CN)
- Central South University (CN)
- Wuhan University (CN)
- Qinghai University Affiliated Hospital (CN)
- Hunan Cancer Hospital (CN)
- Zhongnan Hospital of Wuhan University (CN)
- The First People's Hospital of Changde (CN)
- Yueyang Second People's Hospital (CN)
- Hubei Cancer Hospital (CN)
- University of South China (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1093/oncolo/oyaf277
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- China Primary Health Care Foundation
- Natural Science Foundation of Hunan Province